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ABSTRACT
Pulmonary arterial hypertension (PAH) is an incurable cardiovascular disease
characterized by high blood pressure in the arteries leading from the heart to the lungs.
Over 2 million people in the United States are diagnosed with PAH annually and the
typical survival rate is only 3 years after diagnosis (Archer, Weir et al. 2010). Current
treatments are insufficient because of limited bioavailability, toxicity, and cost
associated with approved therapeutics. Aerosol delivery of drugs is an attractive
approach to treat respiratory diseases because it increases localized drug concentration
while reducing systemic side effects. Dry powder inhalers (DPIs) allow for increased
physicochemical stability of drugs and increased patient compliance. Dry powder
aerosols can be easily designed to meet certain specifications including size,
morphology, and crystallinity via spray drying (Meenach, Vogt et al. 2013).
Tacrolimus (TAC) is a drug that has recently been found to be useful in treating PAH
(Spiekerkoetter, Tian et al. 2013). TAC interacts with bone morphogenic protein
receptor type II (BMPR2), which is often mutated or underexpressed in patients with
PAH (Humbert, Morrell et al. 2004). The expression of BMPR2 inhibits vascular
remodeling, thereby reducing blood pressure. Unfortunately, TAC is poorly watersoluble and toxic when delivered systemically over a long period of time, this driving
the

need

for

improved

formulations

Dipalmitoylphosphatidylcholine

(DPPC)

and

delivery

of

the

compound.

and

dipalmitoylphosphatidylglycerol

(DPPG) are phospholipids naturally present in the lungs that act as a biodegradable
surfactant when used in a 3:1 ratio as an excipient in dry powder microparticles. DPPC
and DPPG can improve particle migration in the lungs and increase lung residence

time (Hadinoto, Phanapavudhikul et al. 2007). I hypothesize that targeting the delivery
of tacrolimus to the lungs using phospholipid-based dry powder aerosol microparticles
will result in increased localized drug concentrations, improving the treatment of
pulmonary arterial hypertension and decreasing the severity of side effects
experienced by patients.
In this study, phospholipid-based aerosol microparticles were developed via spray
drying. These particles were shown to be smooth and spherical in size, ranging from
1-3 µm in diameter. The microparticles exhibited thermal stability and were found to
be amorphous after spray drying. Water content in the microparticles was under 10%,
which will allow successful aerosol dispersion and long-term storage stability. In vitro
aerosol dispersion showed that the microparticles could successfully deposit in the
deep lung, as they exhibited favorable aerodynamic diameters and high fine particle
fractions. In vitro dose-response analysis showed that TAC is nontoxic in the low
concentrations that would be delivered to the lungs. Overall, this work shows that
tacrolimus-loaded phospholipid-based microparticles can be successfully created with
optimal physicochemical characteristics.
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CHAPTER 1

INTRODUCTION

1.1 Background and Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, incurable cardiovascular
disease with a 15% annual mortality rate. PAH involves an increase in pulmonary
vascular resistance due to pulmonary arterial obstructions and can eventually lead to
right ventricular failure and ultimately death. Annually, 2.4 new cases are diagnosed
per million people (Archer, Weir et al. 2010) and there is a mean life expectancy of 3
years after diagnosis with PAH (Saigal, Ng et al. 2013). It is likely that the worldwide
impact of pulmonary arterial hypertension is much more widespread than current
diagnoses suggest due to the difficulty of accurately diagnosing patients.
Vasoconstriction, remodeling of the pulmonary vessel wall, and thrombosis cause
increased pulmonary vascular resistance in PAH patients. The characteristic
pathogenesis of PAH is pulmonary arterial obstruction caused by vascular
proliferation and remodeling, which occurs in all layers of the vessel wall (Humbert,
Morrell et al. 2004). In Figure 1, the heart and lungs of a healthy adult are compared
to those of an adult with PAH. Pulmonary arterial hypertension is defined by a mean
pulmonary artery pressure of 25 mm Hg at rest and 30 mm Hg while exercising
(Rosenblum 2010). PAH can be idiopathic, familial, related to connective tissue
disease, or caused by drug or toxin exposure. Idiopathic, familial, and anorexigenassociated PAH have similar clinical, functional, and hemodynamic characteristics

1

(Humbert, Sitbon et al. 2010). Features of PAH include intimal fibrosis, distal
localization and proliferation of vascular smooth muscle, and pulmonary arterial
occlusion. PAH is also associated with alterations in the rates of cellular proliferation
and apoptosis, resulting in thickened arteries. Severe end stages of PAH often result in
plexiform lesions due to disorganized endothelial cell proliferation (Humbert, Morrell
et al. 2004). Hormones, growth factors, neurotransmitters, and environmental stresses
can promote the development of PAH. One of the primary causes of PAH progression
is an imbalance of the neurochemical mediators that help maintain the vascular tones
of pulmonary arteries (Gupta, Rawat et al. 2010). The prostacyclin, nitric oxide, ion
channels, endothelin-1, and serotonin pathways have been connected with PAH.
Bone morphogenic protein receptor type II (BMPR2) is an active serine/threonine
kinase receptor, which signals via the formation of heterocomplexes in response to
ligands (Humbert, Morrell et al. 2004). BMPR2 plays a large role in familial and
idiopathic PAH, but is not likely to be the root cause of PAH. Genetic and
environmental factors are thought to play a larger role (Hong, Lee et al. 2008).
BMPR2 gene mutations are found in more than 70% of cases of familial PAH and
10% to 40% of apparently sporadic or anorexigen-associated PAH (Humbert, Sitbon
et al. 2010). In cases of PAH without a BMPR2 mutation, BMPR2 expression is still
significantly reduced (Humbert, Morrell et al. 2004). Improving the signaling of
BMPR2 reduces damaging vascular remodeling and can potentially improve patient
symptoms and outcomes (Spiekerkoetter, Tian et al. 2013).
Current therapies for the treatment of pulmonary arterial hypertension include
prostanoids, endothelin receptor blockers, phosphodiesterase type 5 (PDE5) inhibitors,
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and soluble guanylate cyclase (SGC) stimulators that are typically delivered orally or
intravenously. These therapeutics are often paired with anticoagulation and diuretic
drugs due to the risk of thrombosis and edema associated with these treatments
(Archer, Weir et al. 2010). Prostanoids, such as Flolan® and Remodulin®, are often
used to reduce inflammation and vasoconstriction by targeting the prostacyclin
pathway. These compounds inhibit cells in the middle of blood vessels from growing
into lesions (Feldman). Prostanoids are typically considered the best treatment option,
but the dosage forms used limit patient compliance and cause negative systemic side
effects (Saigal, Ng et al. 2013). Endothelin receptor blockers, such as Letairis®, inhibit
the endothelin pathway, which normally causes vasoconstriction by promoting the
growth of cells in the middle of blood vessels resulting in the formation of lesions.
PDE5 inhibitors and SGC stimulators both target the nitric oxide pathway. PDE5
inhibitors, such as Revatio®, decrease the effect of PDE5, thereby increasing the
concentration of nitric oxide in the blood. SGC stimulators, such as Adempas®,
stimulate SGC in cells, causing an increased production of cyclic GMP, causing the
pulmonary arteries to relax (Feldman). These treatments are highly expensive and
difficult to deliver due to their limited bioavailability and toxicity of the drugs.
Frequent dosing of these drugs is required because they have short half-lives. In
addition, current therapies do not inhibit remodeling and patients are often required to
receive heart and lung transplantations to increase their chances of survival
(Spiekerkoetter, Tian et al. 2013). Unfortunately, the progression of PAH and its
treatments are primarily based on assessments of exercise performance, quality of life,
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time to clinical deterioration, and physiological performance because lung tissue for
diagnosis is difficult to obtain other than upon autopsy (Stacher, Graham et al. 2012).
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Figure 1. Comparison of the physiological characteristics of a healthy heart and a
heart with pulmonary hypertension from Nationwide Children’s Hospital.
http://www.nationwidechildrens.org/pulmonary-hypertension
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The limited bioavailability of current PAH therapeutics and their associated toxicity
results in the need for more sophisticated formulations to aid in patient compliance
and health.

1.2 Aerosolized Therapeutics Produced via Spray Drying
Aerosols are a common method used in treating a variety of pulmonary diseases
because they allow for a faster onset of action, avoid the first-pass metabolism of the
liver, which removes the drug from the body before it can reach the target organ, and
result in low systemic drug concentrations. The lungs are an attractive approach for
drug delivery because they are highly permeable and have a large surface area (35-140
m2), allowing for higher bioavailability within the lungs (Shoyele and Cawthorne
2006). In addition, they have an elevated blood flow of 5 L/min (Bosquillon, Lombry
et al. 2001). The lungs have a small fraction of drug-metabolizing and efflux
transporter activity compared to the gut and liver, resulting in drugs delivered through
the lungs producing fewer complex metabolites, thereby increasing drug efficacy
(Patton, Fishburn et al. 2004).
The bronchial airways in human lungs have pseudostratified, ciliated, mucusproducing cells, covered with approximately 8 µm of mucus (Haghi, Traini et al.
2012). Particles that are delivered to the lungs as aerosols can produce a concentration
gradient, causing the particles to undergo dissolution and solute transport across lung
mucus and epithelium (Grainger, Greenwell et al. 2009). The rate of absorption in the
lungs can improve pharmacokinetic profiles both locally in the lungs and systemically
throughout the body (Forbes and Ehrhardt 2005). Targeted delivery to the lungs can be
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enhanced by using microparticles as they can effectively deposit in the lungs by
physical sedimentation (Li and Mansour 2011). Nebulizers, pressurized metered doze
inhalers (pMDIs), soft-mist inhalers (SMIs), and dry powder inhalers (DPIs) are
among the most frequently used aerosol delivery devices. Nebulizers are large and
need to be used frequently for long periods of time and pMDIs require a propellant,
causing these methods to be inconvenient to patients (Suarez and Hickey 2000). DPIs
are beneficial because they allow for the delivery of particles designed with specific
characteristics (particle size, drug loading, etc.) and the resulting dry powder particles
and DPIs provide improved long-term chemical and physical stability (Meenach, Vogt
et al. 2013). DPIs are also advantageous because they are propellant-free, portable,
easy to operate, and inexpensive (Bosquillon, Lombry et al. 2001). They allow for
effective, targeted delivery of drugs to the respiratory tract to treat a variety of
pulmonary diseases. Formulations of dry powder particles delivered via DPIs typically
consist of an active pharmaceutical ingredient (API) and excipient to improve stability
and aerosolization (Guillon, Montharu et al. 2012).
Efficient drug delivery to the lungs using a dry powder inhaler depends on the
inhaler device, powder formulation, and inhalation maneuver (Kaialy, Alhalaweh et al.
2011). The design specifications necessary for successful implementation in DPIs can
easily be met by using advanced spray drying techniques of therapeutics and
excipients for form dry powder aerosol particles. Spray drying is a high-throughput
pharmaceutical particle engineering technique that efficiently produces respirable dry
particles. Spray drying can enable facile control of the size, surface morphology, and
shape of spray-dried particles by altering component concentrations, drying
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temperature, pump rate, and gas flow of the spray-dryer (Iskandar, Gradon et al. 2003,
Hoe, Ivey et al. 2014). There are four steps in a typical spray drying process as seen in
Figure 2. First, the feed solution is atomized into a spray, followed by spray-air
contact (step two). The sprayed droplets are dried at an elevated temperature (step
three) and then the dried particles are separated from the air in a collection vial (step
four) (Chow, Tong et al. 2007). Particle size and morphology play a large role in drug
delivery (Chow, Tong et al. 2007). Optimally sized particles are within 1 to 5 µm for
effective whole-lung deposition (Meenach 2014). Particles below 5 µm can be easily
deposited into the smaller airways, whereas submicron particles will be exhaled
(Chow, Tong et al. 2007). Choosing the correct feed solution when spray-drying
poorly water soluble drugs is extremely important (Paudel, Worku et al. 2013). Using
an organic feed solution can help achieve smaller sized particles with a lower water
content (Li and Mansour 2011). Spray drying also increases the storage stability of
particles due to the reduction in water content (Ré 2006). The short half-lives of drugs
can be improved by developing spray-dried microparticles encapsulated in excipients
such as lipids or polymers (Saigal, Ng et al. 2013).
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Figure 2. The main stages involved in the spray-drying process (Ré 2006).
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Figure 3. Percent deposition in the different sections of the lungs based on
aerodynamic diameter (Laube, Janssens et al. 2011).
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1.3 Tacrolimus
Tacrolimus (TAC), first commercialized as Prograf® in 1990, is a poorly watersoluble immunosuppressive agent derived from the fungus Streptomyces tsukubaensis
(Cho 2014). Normally delivered intravenously or orally, in which it has poor
bioavailability, TAC is typically used in the prevention of organ rejection after
transplantations as an immunosuppressive agent (Gao, Sun et al. 2012). The aqueous
solubility of tacrolimus is low, at 1-2 µg/mL, resulting in in challenges in dosage
formulations (Park, Ryu et al. 2009). When delivered systemically for a prolonged
period of time, TAC causes adverse side effects such as nephrotoxicity, the onset of
diabetes mellitus, an increased risk of opportunistic infections, and neurotoxicity. In
mild cases of neurotoxicity, the patient experiences headaches and tremors, but
patients can experience seizures and delirium in more severe cases (Shin, Cho et al.
2010). TAC has a narrow therapeutic index, making it necessary to closely monitor
patients for toxicity. Severe side effects have been shown to occur at blood
concentrations greater than 50 ng/mL (Watts, Peters et al. 2011). The target trough
range of tacrolimus in the bloodstream is 5-20 µg/L, which requires careful and
invasive monitoring (Sallustio, Noll et al. 2011). By targeting the delivery of TAC to
the lung, the systemic concentration of the drug will be greatly reduced while
increasing local pulmonary drug concentrations and therapeutic levels. Nebulized
TAC has already been shown to improve the response of a lung transplant patient
while substantially reducing side effects (Hayes, Zwischenberger et al. 2010). Blood
levels have been found to remain low after the aerosolization of tacrolimus, reaching
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1.6 ng/mL after twelve hours. (Schrepfer, Deuse et al. 2007). Because of this, patients
will not have to be monitored as closely for systemic levels of TAC.
TAC has been found to be effective in the treatment of pulmonary arterial
hypertension. As mentioned previously, TAC induces the signaling of bone
morphogenic protein receptor type II (BMPR2) in endothelial cells, which has been
found to be dysfunctional in the pathogenesis of pulmonary arterial hypertension by
inhibiting vascular remodeling (Spiekerkoetter, Tian et al. 2013). The chemical
structure of tacrolimus can be seen in Figure 4.

1.4 Phospholipid Excipients
In this study, the active pharmaceutical ingredient tacrolimus was spray dried with
the

excipients

dipalmitoylphosphatidylcholine

dipalmitoylphosphatidylglycerol

(DPPG)

to

produce

(DPPC)
dry

powder

and
aerosol

microparticles. DPPC and DPPG are the primary phospholipid components naturally
present in the lungs. Lung surfactant is composed 80-90% of lipids, 70-80% and 510% of which is made up of phosphatidylcholines (PC) and phosphatidylglycerols
(PG), respectively. Approximately 60% of PC in the lungs is composed of DPPC
(Evora, Soriano et al. 1998). Phospholipids such as DPPC and DPPG are necessary to
support proper lung surfactant function (Meenach, Vogt et al. 2013) and help protect
against infections and inflammation (Mansour, Wang et al. 2001). DPPC and DPPG
are often used in lung surfactant replacement therapies and controlled drug release
applications (Wu, Hayes et al. 2013). Phospholipids are an efficient excipient because
they protect the structural integrity, stability, and fluidity of the drug (Alves and
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Santana 2004). Using phospholipid excipients that are biocompatible and
biodegradable can aid in the delivery of drugs to the lungs by improving particle and
drug migration to the lungs because of the reduction in surface tension from the
surfactant (Evora, Soriano et al. 1998). A large portion of inhaled medications fail to
reach the deep lung, and it is suspected that phospholipid deposition on the mucosal
surface of non-targeted lung areas will cause particles to be transported through the
airways via surfactant spreading (Ganguly, Moolchandani et al. 2008). Phospholipid
excipients may also cause the spray-dried particles delivered to the lungs to evade
recognition and uptake by the immune system, increasing lung residence time
(Meenach, Anderson et al. 2013). In addition, it has been found that the co-spraydrying of drugs with DPPC can help reduce particle size and improve the aerodynamic
performance. In addition, the presence of phospholipids in particles leads to an
improvement in the respirable fine particle fraction (Hadinoto, Phanapavudhikul et al.
2007). The chemical structures of DPPC and DPPG can be seen in Figures 5 and 6.
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Figure 4. Schematic of tacrolimus (TAC).
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Figure 5. Schematic of dipalmatoylphosphatidylcholine (DPPC).
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Figure 6. Schematic of dipalmitoylphosphatidylglycerol (DPPG).
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1.5 Objectives and Hypothesis
The overall objective of this research was to develop and characterize
phospholipid-based aerosol microparticles loaded with tacrolimus for applications in
the treatment of pulmonary arterial hypertension. The specific objectives of this
research include:

1. Synthesis and optimization of phospholipid-based aerosol microparticles
containing tacrolimus using advanced spray drying methods.
2. Evaluation of the physicochemical properties of the spray-dried microparticles
including their size, morphology, drug loading, crystallinity, thermal properties,
water content, and aerosol dispersion.
3. In vitro evaluation of the safety and efficacy of the fully characterized TAC-loaded
microparticles.

The development of an improved delivery method of the drug tacrolimus will
lead to a more effective treatment method for PAH with fewer side effects. A smaller
dose of TAC delivered directly to the lungs can be used than in the oral or intravenous
delivery methods, which should minimize toxicity while optimizing the amount of
drug that reaches the lungs. Targeting the delivery of tacrolimus to the lungs using
phospholipid-based dry powder aerosol microparticles will result in increased
localized drug concentrations, improving the treatment of pulmonary arterial
hypertension and decreasing the severity of side effects experienced by patients. If
delivering dry powder formulated TAC via a DPIs is found to be effective in treating
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PAH, this delivery method could be applied to a multitude of other poorly watersoluble drugs with toxic side effects that are used to treat pulmonary diseases.
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CHAPTER 2

MATERIALS AND METHODS

2.1 Materials
Synthetic dipalmitoylphosphatidylcholine (DPPC, Molecular Weight: 734.05
g/mol, >99% purity) and dipalmitoylphosphatidylglycerol (DPPG, Molecular Weight:
744.96 g/mol, >99% purity) were obtained from Avanti Polar Lipids (Alabaster, AL,
USA). Tacrolimus (TAC, Molecular Weight: 804.02) was obtained from LC
Laboratories (Woburn, MA, USA). 2-Propanol (HPLC grade, 99.9% purity),
Hydranal®-Coulomat, methanol (anhydrous, 99.8% purity), and acetonitrile (HPLC
grade, ≥ 99.9 % purity) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Ultra-high purity (UHP) nitrogen gas was obtained from Airgas (Radnor Township,
PA, USA). Extra pure phosphoric acid (85% pure in water) was obtained from Thermo
Fisher Scientific (Waltham, MA). A549 cells were obtained from ATCC (Manassas,
VA, USA). Sodium pyruvate was obtained from Fisher Scientific. Dulbecco’s
Modified Eagle Medium (DMEM), Pen-Strep, and Fungizone® were obtained from
Life Technologies (Norwalk, CT, USA). Sodium acetate (1 M, pH 5), Triton X-100,
and dimethyl sulfoxide (DMSO) were obtained from Wilkem Scientific (Pawtucket,
RI, USA). Fetal bovine serum (FBS) was obtained from Atlanta Biologics (Flowery
Branch, GA, USA). P-nitrophenyl (pNpp) was obtained from MP Biomedicals (Santa
Ana, CA, USA).

19

2.2 Preparation of Spray-Dried Microparticles
Advanced spray drying of tacrolimus and DPPC/DPPG particles was
performed using a B-290 Büchi Mini Spray Dryer (from Büchi Labortechnik AG,
Switzerland) in closed mode. UHP dry nitrogen was used as the drying gas and the
spray-dried (SD) particles were collected in a sample collector. A nozzle with a
diameter of 0.7 mm was used. The feed solutions were prepared by dissolving DPPC
and DPPG in a 3:1 molar ratio with varying amounts of tacrolimus, including 0, 25,
50, 75 and 100 mol% TAC to the total amount of DPPC/DPPG in isopropanol to form
a dilute solution of 0.5% w/v. The composition of each feed solution can be seen in
Table 1. The spray drying conditions used during particle formation were a pump rate
of 100%, aspiration rate of 100%, and inlet temperature of 100ºC. All spray-dried
powders were stored in small glass vials sealed with parafilm in desiccators with
DrieriteTM desiccant at -20°C under ambient pressure.

2.3 Scanning Electron Microscopy (SEM)
The shape and surface morphology of the spray-dried particles was evaluated
via scanning electron microscopy (SEM) using a Zeiss SIGMA VP Field Emission
Scanning Electron Microscope (Germany). Dry powder samples were placed on
aluminum stubs (Ted Pella Inc., Redding, CA, USA) with double-sided adhesive
carbon tabs and then coated with a thin film of a gold/palladium alloy using a BIORAD sputter coating system at 20 µÅ for 60 seconds under argon gas. Micrographs
were collected at several different magnifications. The size of the spray-dried particles
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was analyzed using Image J Size Analysis software with images obtained from the
SEM at 10x magnification. Fifty particles per sample were analyzed.

2.4 Differential Scanning Calorimetry (DSC)
Thermal analysis and phase transition measurements of the raw materials and
spray-dried particles were carried out via differential scanning calorimetry (DSC)
using a DSC Q10 (TA Instruments, New Castle, DE, USA). 1-2 mg of the sample was
weighed into aluminum Tzero pans with Tzero hermetic lids, both from TA
Instruments. The pans were sealed with Tzero Press from TA Instruments. UHP dry
nitrogen gas was the purging gas used. The samples were exposed to heating range of
-25 to 300 ºC at a heating scan rate of 5 ºC/min.

2.5 Powder X-Ray Diffraction (PXRD)
Powder x-ray diffraction (PXRD) patterns of raw material and particle powder
samples were measured using a Rigaku Multiflex X-ray diffractometer (the
Woodlands, TX, USA) with a slit-detection Cu Kα radiation source (40 kV, 44 mA,
and λ = 1.5406 Å). The scan range was 5-45º in 2θ with a scanning rate of 2 º/min at
ambient temperature. The sample was placed on a horizontal quartz glass sample
holder plate.

2.6 Karl Fischer (KF) Coulometric Titrations
The water content of the raw materials and spray-dried particles was
determined by Karl Fischer (KF) coulometric titration. The measurements were
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performed with an 851 Titrando KF Coulometer coupled with an 803 Ti Stand
(Metrohm Ltd., Antwerp, Belgium). Approximately 10 mg of powder was dissolved in
a known volume of anhydrous methanol. The sample solution was then injected into
the reaction cell containing Hydranal® and the water content was calculated from the
resulting reading.

2.7 In Vitro Aerosol Dispersion Performance by the Next Generation ImpactorTM
(NGITM)
The in vitro aerosol dispersion of the spray-dried microparticles was
determined using a model 170 Next Generation ImpactorTM from MSP Corporation
(Shoreview, MN, USA) with a USP stainless steel induction port. The NGITM was
coupled with a Copley HCP5 vacuum pump and a Copley TPK 2000 critical flow
controller (Copley Scientific, United Kingdom). The airflow rate was set to 60 L/min
in order to model the airflow rate in the lung of a healthy adult (Hickey and Mansour
2009). Glass fiber filters (55 mm, Type A/E, Pall Life Sciences, PA, USA) were
placed into the gravimetric insert cups and weighed before and after each experiment
to determine particle deposition on each stage. Approximately 10 mg of microparticles
were loaded into a hydroxyproyl methylcellulose capsule (HPMC, size 3, Quali-V®,
Qualicaps® Inc, Whitsett, NC, USA) and then placed into a dry powder inhaler
(HandiHaler, Boehringer Ingelheim Pharmaceuticals, CT, USA). The dry powder
inhaler was attached to a rubber mouthpiece attached to the induction port on the
NGITM. The NGITM was operated with a 10 s delay and 10 s run time. The effective
cutoff diameters for each stage of the NGITM were given by the manufacturer as: stage
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1 (8.06 µm); stage 2 (4.46 µm); stage 3 (2.82 µm); stage 4 (1.66 µm); stage 5 (0.94
µm); stage 6 (0.55 µm); and stage 7 (0.34 µm). The mass median aerodynamic
diameter (MMAD) and geometric standard deviation (GSD) were calculated using a
Mathematica® program written by Dr. Warren Finlay (Finlay 2001). The fine particle
dose (FPD), fine particle fraction (FPF), respirable fraction (RF), and emitted dose
(ED) were calculated using the following equations:

𝐹𝑃𝐷 = 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑜𝑛 𝑆𝑡𝑎𝑔𝑒𝑠 2 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 7

𝐹𝑃𝐹 =

𝐹𝑃𝐷
𝑥 100%
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑀𝑎𝑠𝑠 𝐿𝑜𝑎𝑑𝑒𝑑 𝑖𝑛𝑡𝑜 𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠

𝑅𝐹 =

𝐸𝐷 =

𝐹𝑃𝐷
𝑥 100%
𝑇𝑜𝑡𝑎𝑙 𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑀𝑎𝑠𝑠 𝑜𝑛 𝑎𝑙𝑙 𝑆𝑡𝑎𝑔𝑒𝑠

𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝑎𝑠𝑠 𝑖𝑛 𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠 − 𝐹𝑖𝑛𝑎𝑙 𝑀𝑎𝑠𝑠 𝑅𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑖𝑛 𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠
𝑥 100%
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝑎𝑠𝑠 𝑖𝑛 𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠

2.8 In Vitro Dose-Response Analysis
A549 lung adenocarcinoma cells were cultured in 75 cm2 Biolite cell culture
flasks (Fisher Scientific) with media consisting of DMEM supplemented with 10%
(v/v) FBS, Pen-Strep (100 U/mL penicillin, 100 µg/mL streptomycin), Fungizone®
(0.5 µg amphotericin, B, 0.41 µg/mL sodium deoxycholate), and 1 mM sodium
pyruvate. The cells were cultured at 37ºC and 5% CO2 in a humidified incubator. The
A549 cells were seeded in two 96 well plates (Celltreat Scientific, Shirley, MA, USA)
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at 100 µL/well. On day two, the cells were dosed with dilutions of TAC ranging from
0.00001 to 10 µM of a 20,000 µM stock solution of raw TAC in DMSO. 0.1% (v/v) of
DMSO was used in each dilution to aid in TAC solubility in media. The control for
the calculations was 0 µM TAC in 0.1 % (v/v) DMSO. 100 µL of the dilutions were
added to each well (n = 8). At 48 and 72 hours after drug exposure, viability of the
cells was assessed using the acid phosphatase assay. A pNpp solution (sodium acetate,
1% Triton X-100, and pNpp) was added to each well and the plate was then incubated
at 37°C and 5% CO2 for two hours. The absorbance was measured at 405 nm with a
Cytation 3 plate reader (BioTek, Winooski, VT, USA). Relative viability was
calculated using the following equation:

𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 % =

𝑆𝑎𝑚𝑝𝑙𝑒 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝑥 100%
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
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CHAPTER 3

RESULTS AND DISCUSSION

The described study involved the physicochemical and in vitro characterization
of tacrolimus-loaded DPPC/DPPG particles produced via spray drying. Optimization
and design resulted in the formulation of several practical particle systems, which
included four systems loaded to tacrolimus (25, 50, 50, and 100 mole% TAC) and one
without (pure phospholipids). This study strived to determine the effects on the
presence of differing TAC amounts on the particle formulations. The size,
morphology, thermal stability and crystallinity, water content, aerodynamic dispersion
performance, and in vitro effects on pulmonary cells were evaluated.

3.1 Size and Morphology of Spray-Dried Microparticles
The formulated particles and their morphologies were analyzed using SEM
micrographs, as seen in Figure 7. The geometric diameter of the particles is displayed
in Table 1 and was determined using Image J software. 0TAC particles were
agglomerated and as a result their diameter was immeasurable. 25TAC and 75TAC
particles were rounder and smoother than 0TAC with some agglomeration and
sintering between particles. 50TAC particles were spherical, smooth, and uniformly
sized. 100TAC particles were round and smooth, but not uniformly sized. The size of
all measurable particles was between 1.20 to 2.83 µm in size as seen in Table 1.
50TAC particles were the largest and 100TAC particles were the smallest. All
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particles were within the range for optimal lung deposition in children and adults
(Meenach 2014). The particles exhibited an ideal size range (approximately 1 µm) for
ensuring targeted delivery to specific regions of the lung. In particular, the geometric
diameters indicate that the described microparticles are capable of delivering a
therapeutic payload to the deep lung (Sung, Pulliam et al. 2007), which is necessary
for the treatment of pulmonary arterial hypertension.
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Figure 7. Representative SEM micrographs of spray-dried phospholipid-based
microparticles: (a) 0TAC; (b) 25TAC; (c) 50TAC; (d) 75TAC; (e) 100TAC, where the
number indicates the mole% of TAC in each system. Magnification = 10,000x. Scale
bar = 5 µm.

27

Table 1. Systems of spray-dried phospholipid-based particles and their corresponding
mole % of tacrolimus (TAC), dipalmitoylphosphatidylcholine (DPPC), and
dipalmitoylphosphatidylglycerol (DPPG), outlet temperature from the spray dryer,
geometric diameter, and water content.

28

3.2 Thermal Analysis of Spray-Dried Microparticles
DSC studies were performed on the raw materials prior to spray drying (TAC,
DPPC, DPPG) and spray-dried formulated microparticles (0TAC, 25TAC, 50TAC,
75TAC, and 100TAC) to determine their thermal behavior and melting points, as seen
in Figure 8. An endothermic peak is evident at 129°C for raw tacrolimus (TAC),
signifying its melting point. The endothermic peak signifying the TAC melting point
is not present in the thermograms of the spray-dried particles due to the transition of
TAC from crystalline to amorphous forms during the spray drying process. Raw
DPPC and DPPG exhibited a characteristic bilayer main phase transition phase at
71°C and 79°C. A bilayer main phase transition was also seen in the spray-dried
microparticles at approximately 76°C, becoming less significant with increasing drug
concentration due to the DPPC content.
The formulated microparticles were spray dried at an inlet temperature of
100°C at a pump rate of 100% (the highest possible for the described system). As a
result, the outlet temperatures of the spray drying process for the microparticles ranged
from 42 to 45°C, as seen in Table 1. These outlet temperatures are below the phase
transition temperatures as indicated in the DSC thermograms, therefore the spray
drying temperatures do not negatively impact the formation of the microparticles. The
stability microparticles at different storage conditions such as room temperature
(22°C), refrigeration (4°C), and freezing (-20°C) is likely since there are no
measurable DSC transition peaks present in the data. This is also true at the treatment
condition (e.g. body temperature at 37°C).
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Figure 8. DSC thermograms of spray-dried microparticles of varying compositions
and their corresponding raw materials (DPPG, DPPC, and TAC).
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3.3 Crystallinity Analysis of Spray-Dried Tacrolimus Microparticles
X-ray powder diffractograms were collected for the raw pre-spray-dried
components (TAC, DPPC, DPPG) and spray-dried microparticles (0TAC, 25TAC,
50TAC, 75TAC, and 100TAC) as shown in Figure 9. Strong peaks are seen in raw
TAC between 20 and 25° 2θ indicating the crystallinity of the material prior to the
spray drying process. Raw DPPC exhibited a strong broad peak at 21° 2θ, which
corresponds to the presence of the phospholipid bilayer structure (Alves and Santana
2004). Raw DPPG showed a cluster of peaks between 18 and 25° 2θ. The spray-dried
particles show decreasing peak intensities at 22° 2θ with increasing mole percentage
of TAC. The peaks corresponding to raw DPPG were not noticeable in the spray-dried
formulations, likely due to their limited presence in comparison to raw DPPC, which
has a strong peak signal. 0TAC and 25TAC exhibited the most evident peaks of the
spray-dried particles at 22° 2θ, indicative of the presence of phospholipid bilayer
structures within the particles. The lack of significant peaks in the 50TAC, 75TAC,
and 100TAC particles is likely due to the lower mole percentage of the phospholipids
and reveals that the TAC present in the spray-dried particles is amorphous and has
limited bilayer formation. Amorphous solids are more soluble and have higher
dissolution rates than crystalline solids (Alves and Santana 2004).
PXRD and DSC analysis indicate that the spray-dried phospholipid TACloaded microparticles display the characteristics of particles with a lipid bilayer
structure (likely multilamellar) owing to the signature peaks in XRD analysis and
bilayer phase transition values in the DSC thermograms (Mansour, Wang et al. 2001,
Mansour and Zografi 2007).
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3.4 Water Content
The residual water content in the spray-dried microparticles can be seen in
Table 1. The water content in the microparticles ranged from 4 to 10%. It was the
highest in 0TAC particles, at 10.01 ± 3.29% and lowest in the 100TAC particles, at
4.15 ± 1.50%. The remaining formulations had 6-7% residual water, similar to
previously reported results (Meenach, Vogt et al. 2013) and within the range of other
microparticles in our group (results not published). Low water content in inhalable dry
powders is essential for aerosol dispersion properties because it reduces agglomeration
(Meenach, Anderson et al. 2013). High water content in aerosol powders and drug
formulations can also reduce stability due to the propensity of amorphous powders to
recrystallize in aqueous conditions (Wu, Hayes et al. 2013).
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Figure 9. X-ray powder diffractograms of spray-dried microparticles with varying
compositions and their corresponding raw materials.
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3.5 In Vitro Aerosol Dispersion Analysis
The most important factor influencing the deposition of particulates to the
lungs are the aerodynamic properties of the therapeutic system (Hickey and Mansour
2009). The in vitro aerosol dispersion performance properties of the microparticles
were evaluated using an NGITM coupled with a DPI device and can be seen in Figure
10 and Table 2. Figure 10 demonstrates the actual aerosol dispersion performance of
the formulated dry powder microparticles by showing the mass fraction of particles on
each NGITM stage. The mass mean aerodynamic diameters (MMAD) of the particles
were 4.0 ± 0.6 µm for 0TAC, 9.1 ± 2.2 µm for 25TAC, 8.7 ± 5.2 µm for 50TAC, 4.1 ±
0.7 µm for 75TAC, and 6.0 ± 1.8 µm for 100TAC. The geometric standard deviation
(GSD) for the spray-dried microparticles ranged from 2.1 ± 0.2 µm to 2.9 ± 0.9 µm
and these values were similar to previously reported results (Meenach, Vogt et al.
2013).
The fine particle fractions (FPF) of the particles ranged from 40.6 to 74.2 %,
the respirable fraction (RF) ranged from 35.8 to 55.7% and the emitted dose (ED)
ranged from 88 to 100%. In addition, as indicated in Figure 10, 21-27% of
microparticles deposited on stages 2-4 and 1-6% deposited on stages 5-7. There were
no clear trends corresponding to the effect of amount of drug in relation to excipient
on the aerosol dispersion properties of the microparticles. The particles with the most
optimal aerosol performance were the 75TAC particles. Overall, aerosol dispersion
was measurable on all of the NGITM stages and as a result these microparticles are
predicted to deposit in the deep lung region of the human lung as well as throughout
the upper portions of the lung as indicated by the MMAD values.
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Figure 10. In vitro aerosol dispersion performance as mass fraction of microparticles
deposited on each stage of the Next Generation ImpactorTM (NGITM) for spray-dried
particles containing DPPC and DPPG with varying PTX content. For Q = 60 L/min,
the effective cutoff diameters (D50) for each NGITM impaction stage are as follows:
stage 1 (8.06 µm), stage 2 (4.46 µm), stage 3 (2.82 µm), stage 4 (1.66 µm), stage 5
(0.94 µm), stage 6 (0.55 µm), and stage 7 (0.34 µm). (n = 3, Average ± SD).
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Table 2. In vitro aerosol dispersion performance using the Next Generation
ImpactorTM for spray-dried phospholipid-based systems containing tacrolimus.
Parameters include mass median aerodynamic diameter (MMAD), geometric standard
deviation (GSD), fine particle fraction (FPF), respirable fraction (RF), and emitted
dose (ED) (n = 3, Average ± SD).
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3.6 In Vitro Dose-Response Analysis
The effect of raw tacrolimus on the viability of A549 cells was evaluated at 48
and 72 hours after drug exposure and can be seen in Figures 11 and 12, respectively.
The relative viability for the A549 cells remained steady for increasing drug
concentrations for both the 48 and 72-hour studies, showing that TAC is not toxic to
lung cells at concentrations ranging from 0.00001 µM to 10 µM. In greater
concentrations, the drug does become toxic (data not shown), but drug concentration
in the lungs would not exceed this range, particularly in the spray-dried microparticles
(Hayes, Zwischenberger et al. 2010). Delivering TAC to the lung is not expected to
cause cell death, minimizing potential negative side effects.
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Figure 11. 48-hour dose-response curve for A549 cells exposed to tacrolimus.
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Figure 12. 72-hour dose-response curve for A549 cells exposed to tacrolimus.
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CHAPTER 4

CONCLUSIONS AND FUTURE WORK

4.1 Conclusions
Dry

powder

aerosol

microparticles

dipalmitoylphosphatidylcholine

(DPPC),

containing
and

of

tacrolimus

(TAC),

dipalmitoylphosphatidylglycerol

(DPPG) were successfully formulated via spray drying and exhibited optimal
characteristics for dry powder aerosols used for the treatment of pulmonary arterial
hypertension. Five different formulations were made with a 3 to 1 molar ratio of
DPPC to DPPG and varying drug concentrations (0%, 25%, 50%, 75%, and 100 mole
% TAC). The physicochemical characteristics of the microparticles were evaluated
prior to in vitro cellular analysis. 0TAC did not form distinguishable microparticles,
but the remaining formulations ranged from 1.5 - 2.5 µm in size. 50TAC and 75TAC
particles were spherical and smooth with a narrow size distribution. The
microparticles were found to be stable in the working temperature range with no
measurable thermal degradation. The spray drying process resulted in amorphous
microparticles, which can improve drug solubility. Water content in the microparticles
was low, which is essential for dry powder aerosolization and formulation stability.
The in vitro aerosol dispersion showed that these microparticles are optimal for whole,
and in particular, deep lung deposition for drug delivery. Dose-response analysis
showed that the concentrations of tacrolimus that will be present in the lungs would be
nontoxic.
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This study successfully showed that tacrolimus-loaded microparticles can be
produced that may reduce toxicity. These systems demonstrated the successful use of
biocompatible phospholipids as excipients in improving aerosol dispersion and
particle size for the targeted delivery of dry powder particles. This method can
improve the treatment of pulmonary arterial hypertension by effectively delivering
tacrolimus in a way that minimizes side effects, improves stability, and increases
patient convenience.

4.2 Future Work
Future work includes the analysis of the drug loading and encapsulation
efficiency of tacrolimus in the spray-dried microparticles, the evaluation of impact of
the microparticles on the transepithelial electrical resistance of Calu-3 cells, and the
dose response of the microparticles on A549 cells. Overall, the use of DPPC and
DPPG as excipients in spray-dried microparticles for dry powder delivery could easily
be applied to a multitude of other poorly water-soluble drugs with toxic side effects
that are used to treat pulmonary diseases.
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